The Brexit, the Quitaly, generally high unemployment, the ripping apart of the E.U., low stagnating growth, double- and triple-dip recessions — you name it, the Old Country is suffering from it. With that in mind, European stocks certainty aren’t at the top of investor’s lists when it comes hot investment destinations. After all, would you really want to plunk a pile of hard-earned....More>>>
Donald Trump’s win has done something extraordinary to the financial sector. Just look at this one-month chart for the Financial Select Sector SPDR ETF (XLF):
Banks Love Trump
This is unexpected on two levels.
First, of course, Trump’s very election came as a shock to many. Second, there was no shortage of people saying stocks would tank if the real estate mogul....More>>>
Palo Alto Networks (NYSE:PANW) is scheduled report FYQ4 results on 8/30, after the market close. After reading some of the publicly available earnings previews out there, which I think are highly dissatisfactory, I decided to write my own for the benefit of the retail investor. I hope this preview will help you gain more insight into the key debate points going into PANW’s earnings and also....More>>>
Treasury yields rose Friday as bond investors put several potentially market-moving events in the rearview mirror and began to look ahead to next weeks auctions of government paper and a meeting of Federal Reserve policy makers.
The yield on the 2-year note, which is sensitive to Fed policy, ....More>>>
We’ve noted before that for all the attention Macau gets, the real action for casinos these days is in Las Vegas. In a report issued today, Gabelli’s Adam Trivison touts the importance of Nevada for Boyd Gaming (BYD) and MGM Resorts International (MGM), which have large Nevada footprints, and for Wynn Resorts (WYNN) and Las Vegas Sands (LVS), which don’t:
After the company reported positive results from a mid-stage study evaluating its novel approach to tackling blood cancer, shares in Kite Pharma, Inc. (NASDAQ:KITE) surged 34.6% higher in February, according to S&P Global Market Intelligence.
Kite Pharma’s lead product candidate is axicabtagene ciloleucel, a chimeric antigen receptor T-cell....More>>>
Related SLB JPMorgan Sees Opportunity In Oil Services, Says M&A Will 'Take Backseat' Morgan Stanley Recaps Houston E&P Conference With 5 Takeaways On Oil Drillers Whole Foods Turnaround Is Real – Cramer's Lightning Round (5/20/16) (Seeking Alpha) ....More>>>
You might have heard that there were some big changes at Alcoa (AA), which is now bereft of its “downstream,” “value-add” business, Arconic (ARNC). Citigroup’s Alexander Hacking and Jessica Idiculla contend Alcoa will be fine on its own:
Photo: Sean Gallup/Getty Images
We initiate coverage on Alcoa Corporation with a Buy rating and $30/sh target....More>>>